Your browser does not support iframes.
In the Beginning...
Established in Jerusalem in 1901, the company known today as Teva starts out as a small wholesale drug business that distributes imported medications.
A New Pharmaceutical Industry is FoundedConditions are ripe for establishing a local pharmaceutical industry. New manufacturing plants are founded and quickly gain momentum. During World War II, these plants are the sole source of pharmaceutical supplies for the local market, neighboring countries and the British Army stationed in the Middle East.
Expansion of the Local Drug MarketWith the founding of the State of Israel, the local drug market expands rapidly. Established pharmaceutical manufacturing companies grow, including Teva. While most are privately owned, Teva begins trading on the Tel Aviv Stock Exchange in 1951.
Consolidation of the Local Pharmaceutical IndustryA period of consolidation in the Israeli pharmaceutical industry beginning in the 1960s culminates with the 1976 union of Teva, Assia, and Zori to create Israel’s largest drugmaker, Teva Pharmaceutical Industries Ltd. Teva takes its first step abroad into Europe.
Going International - Worldwide ExpansionTeva expands internationally, capitalizing on the passing of the Hatch-Waxman Act to enter the US market in the generics sector. Teva begins trading on NASDAQ, marking the start of a period of robust growth.
Extending a Strong Multinational PresenceTeva’s first major new drug, Copaxone® for the treatment of Multiple Sclerosis (MS), is approved by the FDA. Teva invests in a series of acquisitions that extend its global reach in the US and Europe. The company assumes leadership of the US generics sector.
Acquisition of Copley Pharmaceuticals Inc. – USA
A Leader in Global MarketsTeva continues to invest in major acquisitions of Canadian, US and EU pharmaceutical companies with subsidiaries in Latin America and elsewhere. Teva becomes the largest generic pharmaceutical company in North America, and strengthens its worldwide presence while broadening its pipeline and product offerings.
Acquisition of German ratiopharm significantly increases Teva's market share in Europe, harnessing ratiopharm's excellent foundation for biosimilars, branded generics and tenders.
The World's Largest Medicine CabinetTeva provides medicines to 200 million people around the world every day.Teva has one of the most competitive operational networks in the industry, with sales in approximately 100 global markets and a portfolio of 16,000 products, spanning generics, specialty and OTC.
Acquisition of NuPathe Inc. in the US.
In February 2015, Teva entered into an exclusive license agreement with Eagle for Bendeka™ to strengthen its Treanda® franchise for the treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin’s lymphoma.
In May 2015, Teva acquired Auspex, in a deal expected to strengthen Teva's core central nervous system franchise with SD-809 (deutetrabenazine), developed to treat several movement disorders.
During 2015, Teva acquired stakes in Gecko Health Innovations, Inc., Immuneering Corporation and Microchips Biotech, Inc.
In March 2016, Teva acquired Rimsa in Mexico.
In April 2016, Teva established a business venture with Takeda, Japan's largest pharmaceutical company. The business venture seeks to leverage Takeda’s leading brand reputation and strong distribution presence in Japan with Teva’s expertise in supply chain, operational network, infrastructure and R&D, ultimately serving millions of patients in the growing generic market of Japan.
In August 2016, Teva acquired Allergan plc’s worldwide generic pharmaceuticals business, Actavis Generics, significantly expanding Teva’s generics product portfolio, R&D capabilities, product pipeline and global operational network. The acquisition strongly reinforces Teva’s strategy, accelerates the creation of its new business model and opens a new set of possibilities for the company in generics.
In September 2016, Teva and Regeneron entered into a collaboration agreement to develop and commercialize Regeneron’s pain medication product, Fasinumab.
In October 2016, Teva and Celltrion entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar products in the US and Canada.
In October 2016, Teva acquired Anda, a leading distributor of generic pharmaceuticals in the US. This strategic move enables Teva to improve capabilities and flexibility in order to provide access to more patients throughout the US.
Dr. Yitzhak Peterburg appointed as Teva's Interim President & CEO